HC Wainwright Reiterates Buy Rating for Emergent BioSolutions (NYSE:EBS)

Emergent BioSolutions (NYSE:EBS)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They presently have a $15.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target suggests a potential upside of 118.98% from the company’s previous close.

A number of other research analysts have also recently weighed in on the stock. StockNews.com upgraded shares of Emergent BioSolutions from a “hold” rating to a “buy” rating in a research note on Monday, February 17th. Benchmark boosted their price objective on Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, November 7th.

Emergent BioSolutions Stock Down 8.4 %

NYSE EBS opened at $6.85 on Tuesday. Emergent BioSolutions has a 52 week low of $1.82 and a 52 week high of $15.10. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30. The company has a market capitalization of $371.16 million, a P/E ratio of -1.67 and a beta of 1.62. The stock’s 50-day moving average price is $9.52 and its 200-day moving average price is $9.08.

Emergent BioSolutions (NYSE:EBS) last released its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.40. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. The company had revenue of $194.70 million for the quarter, compared to analysts’ expectations of $254.67 million. During the same quarter last year, the business earned ($0.77) EPS. On average, equities research analysts predict that Emergent BioSolutions will post -0.63 earnings per share for the current year.

Hedge Funds Weigh In On Emergent BioSolutions

Several hedge funds have recently modified their holdings of the stock. B. Riley Wealth Advisors Inc. lifted its stake in Emergent BioSolutions by 21.9% in the 4th quarter. B. Riley Wealth Advisors Inc. now owns 41,800 shares of the biopharmaceutical company’s stock worth $400,000 after purchasing an additional 7,500 shares in the last quarter. Alpine Global Management LLC purchased a new stake in shares of Emergent BioSolutions in the fourth quarter worth about $112,000. Two Sigma Advisers LP lifted its position in shares of Emergent BioSolutions by 14.1% in the fourth quarter. Two Sigma Advisers LP now owns 656,500 shares of the biopharmaceutical company’s stock worth $6,276,000 after buying an additional 81,000 shares in the last quarter. Two Sigma Investments LP boosted its stake in Emergent BioSolutions by 13.9% during the fourth quarter. Two Sigma Investments LP now owns 846,766 shares of the biopharmaceutical company’s stock valued at $8,095,000 after buying an additional 103,574 shares during the last quarter. Finally, State of Wyoming grew its holdings in Emergent BioSolutions by 118.2% during the 4th quarter. State of Wyoming now owns 39,076 shares of the biopharmaceutical company’s stock valued at $374,000 after buying an additional 21,165 shares in the last quarter. Hedge funds and other institutional investors own 78.40% of the company’s stock.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.